Side Effects of Trimetazidine
Trimetazidine is generally well-tolerated with mild adverse effects, primarily consisting of gastrointestinal disturbances (nausea, vomiting, minor headaches), but carries critical contraindications in patients with Parkinson disease, parkinsonism, other movement disorders, and severe renal impairment (creatinine clearance <30 ml/min). 1
Common and Mild Side Effects
The most frequently reported adverse effects are:
- Gastrointestinal disturbances including nausea, vomiting, and diarrhea 1, 2, 3
- Minor headaches 1
- Drowsiness and sedation 2
These side effects occur at low incidence and are generally well-tolerated by patients. 3 In comparative studies, trimetazidine demonstrated a superior tolerability profile to nifedipine, with significantly fewer side effects (5 patients vs 13 patients, p = 0.03). 2
Critical Contraindications and Warnings
Movement Disorders
Trimetazidine is not recommended in patients with Parkinson disease, parkinsonism, and other related movement disorders. 1 This represents the most serious safety concern with trimetazidine, as Parkinsonian symptoms have emerged as a notable adverse effect that can outweigh benefits in susceptible patients. 4
Renal Impairment
Trimetazidine should not be used in patients with severe renal impairment (creatinine clearance <30 ml/min). 1
Safety Profile in Clinical Practice
The overall safety profile of trimetazidine is favorable:
- Treatment-related adverse events occur at very low incidence (0.7%) in real-world studies 5
- The tolerability profile is similar to placebo when used as add-on therapy in patients with inadequately controlled angina 3
- Only minor side effects have been reported in large-scale clinical trials 2
- 85% of patients remain on trimetazidine combination therapy over 4-month follow-up periods, indicating good tolerability 5
Comparative Safety
When compared to traditional antianginal agents:
- Superior tolerability to nifedipine 40 mg/day with significantly lower incidence of adverse events 3
- Similar or better tolerability than propranolol 120-160 mg/day 3
- No hemodynamic side effects (no changes in heart rate, blood pressure, or rate-pressure product), unlike traditional antianginal agents 1
Clinical Monitoring Considerations
While trimetazidine has a favorable safety profile, clinicians should:
- Screen for pre-existing movement disorders before initiating therapy 1
- Assess renal function and avoid use if creatinine clearance is <30 ml/min 1
- Monitor for gastrointestinal symptoms, though these are typically mild and self-limiting 1
- Be aware that serious adverse effects are rare, with most patients tolerating the medication well 3, 5